Measurement of antiretroviral drugs in the lungs of HIV-infected patients

HIV Therapy

Volumn 4, Issue 2, 2010, Pages 247-251

  Twigg, Homer L ^a   Schnizlein Bick, Carol T ^a   Weiden, Michael ^b   Valentine, Fred ^b   Wheat, Joseph ^a   Day, Richard B ^a   Rominger, Helen ^a   Zheng, Lu ^c   Collman, Ronald G ^d   Coombs, Robert W ^e   Bucy, R Pat ^f   Rezk, Naser L ^g   Kashuba, Ngela DM ^g  

^a INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Bronchoalveolar lavage; Drug concentration; Efavirenz; HAART; HIV RNA; Lung

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; VIRUS RNA;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG EXPOSURE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG; LUNG LAVAGE; RECEIVER OPERATING CHARACTERISTIC; VIRUS LOAD;

EID: 77951696598     PISSN: 17584310     EISSN: None     Source Type: Journal    
DOI: 10.2217/hiv.10.5     Document Type: Article

References (14)

1. Murray JF, Mills J: Pulmonary Infectious complications of human immunodeficiency virus infection. Part II. Am. Rev. Respir. Dis. 141, 1582-1598 (1990).
2. Murray JF, Mills J: Pulmonary infectious complications of human immunodeficiency virus infection. Part I. Am. Rev. Respir. Dis. 141, 1356-1372 (1990). (Pubitemid 20172595)
3. Wolff AJ, O'Donnell AE: Pulmonary manifestations of HIV infection in the era of highly active antiretroviral therapy. Chest 120, 1888-1893 (2001).
4. Johnson SC, Gerber JG: Advances in HIV/AIDS therapy. Adv. Intern. Med. 45, 1-40 (2000).
5. Twigg III HL, Weiden M, Valentine F et al.: Effect of highly active antiretroviral therapy on viral burden in the lungs of HIV-infected subjects. J. Infect. Dis. 197, 109-116 (2008).
6. Twigg III HL, Soliman DM, Day RB et al.: Lymphocytic alveolitis, bronchoalveolar lavage viral load, and outcome in human immunodeficiency virus infection. Am. J. Respir. Crit. Care Med. 159, 1439-1444 (1999).
7. Choi SO, Rezk NL, Kashuba AD: High-performance liquid chromatography assay for the determination of the HIV-protease inhibitor tipranavir in human plasma in combination with nine other antiretroviral medications. J. Pharm. Biomed. Anal. 43, 1562-1567 (2007).
8. Rezk NL, Crutchley RD, Kashuba AD: Simultaneous quantification of emtrickabine and tenofovir in human plasma using high-performance liquid chromatography after solid phase extraction. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 822, 201-208 (2005).
9. Rezk NL, Tidwell RR, Kashuba AD: Simultaneous determination of six HIV nucleoside analogue reverse transcriptase inhibitors and nevirapine by liquid chromatography with ultraviolet absorbance detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 791, 137-147 (2003).
10. Rennard SI, Basset G, Lecossier D et al.: Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J. Appl. Physiol. 60, 532-538 (1986).
11. Pea F, Viale P: The antimicrobial therapy puzzle: could pharmacokineticpharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients? Clin. Infect. Dis. 42, 1764-1771 (2006).
12. Torre D, Speranza F, Martegani R: Impact of highly active antiretroviral therapy on organ-specific manifestations of HIV-1 infection. HIV Med. 6, 66-78 (2005).
13. Guadalupe M, Sankaran S, George MD et al.: Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection. J. Virol. 80, 8236-8247 (2006).
14. Boffito M, Pillay D, Wilkins E: Management of advanced HIV disease: resistance, antiretroviral brain penetration and malignancies. Int. J. Clin. Pract. 60, 1098-1106 (2006).